Use of Fenoldopam for the treatment of Hemolytic Uremic SyndromeW O 2 0 1 8 / 0 5 8 4 6 6
- Treatment of Hemolytic Uremic Syndrome to reduce kidney damage.
- Prevention and treatment of Acute Kidney Injury.
– Key Benefits
- Improved kidney perfusion in Hemolytic Uremic Syndrome and in other renal diseases with reduced organ perfusion.
- Licensing out.
Second medical use of Fenoldopam for the treatment of Hemolytic Uremic Syndrome.
Hemolytic uremic syndrome (HUS) is a severe clinical condition characterized by platelet consumption, hemolysis and multi-organ hypoxic/ischemic damage (particularly the kidney and the brain). Its incidence is very different according to geographic conditions but in Western countries it is the main cause of acute kidney failure in children. Although more common in children, the disease can also involve adults. To date there is no specific treatment for hemolytic uremic syndrome from STEC (Shiga-like toxin-producing Escherichia Coli) and patient management relies upon support measures only: red blood cell transfusions, antihypertensive therapy, dialysis, anticonvulsant drugs, respiratory and resuscitative care.
Policlinico Hospital Researchers tested the use of Fenoldopam, a Dopamine receptor selective (D1) agonist with vasodilatory properties, in HUS demonstrating a significant reduction of the Renal Resistance Index (without systemic hemodynamic effect) thus of hypoxic/ischemic organ damage in patients.
- Patent granted in Italy.
- Patent application filed in Europe, US, India, Israel, Brasil.
- Gianluigi Ardissino.
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan - Italy